Novavax's stock rockets after late-stage trial for flu treatment achieves primary endpoints [MarketWatch]
Novavax, Inc. (NVAX)
Last novavax, inc. earnings: 3/11 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.novavax.com/investor-relations
Company Research
Source: MarketWatch
Novavax's stock rockets after late-stage trial for flu treatment achieves primary endpoints Shares of Novavax Inc. NVAX, +3.96% rocketed 37% in premarket trading Tuesday, after the biotechnology company said its NanoFlu treatment for seasonal flu achieved all primary endpoints in a phase 3 trial for adults 65 an older. NanoFlu was well tolerated and had a safety profile comparable to Fluzone Quadrivalent. "These strong Phase 3 results align with and validate our previous clinical trials, in which NanoFlu showed higher HAI antibody responses than the leading flu vaccine for older adults," said Chief Executive Stanley Erck. "We expect that both Fast Track designation and the accelerated approval pathway from the FDA will help Novavax bring NanoFlu to market as quickly as possible to address the serious public health threat of influenza." The stock has nearly tripled (up 169%) over the past three months through Monday, while the iShares Nasdaq Biotechology ETF IBB, -0.55% has lost
Show less
Read more
Impact Snapshot
Event Time:
NVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVAX alerts
High impacting Novavax, Inc. news events
Weekly update
A roundup of the hottest topics
NVAX
News
- Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action SettlementAccesswire
- Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action SettlementAccesswire
- RSV Vaccine Market To Reach USD 2.2 Billion By 2032 | DataHorizzon Research [Yahoo! Finance]Yahoo! Finance
- Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action SettlementAccesswire
- Hedge fund Shah Capital recommends two new candidates for Novavax board [Reuters]Reuters
NVAX
Earnings
- 2/28/24 - Miss
NVAX
Sec Filings
- 4/26/24 - Form 8-K
- 4/15/24 - Form SC
- 4/15/24 - Form SC
- NVAX's page on the SEC website